At a glance
ClinicalIndex Comparison RecordN/ACompleted· 436 enrolled
Drug / intervention
Gelesis100 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
In Brief
A clinical study evaluating Gelesis100 and placebo for Overweight and Obesity. Completed, enrolled 436 participants across 36 sites in 6 countries.
Detailed Summary
This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight, Obesity
CountriesCanada, Czechia, Denmark, Italy, Spain, United States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedDec 2014
Primary CompletionJun 2017
TodayJul 2026
First PostedDec 4, 2014
Enrollment StartNov 1, 2014
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.6 years ago
Interventions
Gelesis100device
placebodevice